May a copd patient benefit from rehabilitation associated with pharmacological treatment?;Czy chory na POChP odnosi korzyści z rehabilitacji skojarzonej z leczeniem farmakologicznym?

Pneumonologia i Alergologia Polska

Volumn 80, Issue 5, 2012, Pages 463-466

  Kozielski, Jerzy ^a  

^a la skiego Uniwersytetu Medycznego w Zabrzu   (Poland)

Author keywords

COPD; Pharmacological treatment; Rehabilitation

Indexed keywords

BRONCHODILATING AGENT; GLUCOCORTICOID;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; EXERCISE TOLERANCE; HEALTH STATUS; HUMAN; MULTIMODALITY CANCER THERAPY; PHYSIOTHERAPY; QUALITY OF LIFE; SPIROMETRY; TREATMENT OUTCOME;

BRONCHODILATOR AGENTS; COMBINED MODALITY THERAPY; EXERCISE TOLERANCE; GLUCOCORTICOIDS; HEALTH STATUS; HUMANS; PHYSICAL THERAPY MODALITIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SPIROMETRY; TREATMENT OUTCOME;

EID: 84865831612     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Kozielski J. Przewlekła obturacyjna choroba płuc w oczach chorych i lekarzy. Alerg. Astma Immun. 2004; 9: 175-177.
2. Pitta F., Troosters T., Spruit M.A., Probst V.S., Decramer M., Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 171: 972-977.
3. Al-Shair K., Dockry R., Mallia-Milanes B., Kolsum U., Singh D., Vestbo J. Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD. Respir. Med. 2009; 103: 1572-1579.
4. O'Donnell D.E. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2006; 3: 180-184.
5. Hannink J.D., van Helvoort H.A., Dekhuijzen P.N., Heijdra Y.F. Dynamic hyperinflation during daily activities: does COPD global initiative for chronic obstructive lung disease stage matter? Chest 2010; 137: 1116-1121.
6. Troosters T., Sciurba F., Battaglia S. i wsp. Physical inactivity in patients with COPD, a controlled multi-center pilot-study. Respir. Med. 2010; 104: 1005-1011.
7. Casaburi R. Impacting patient-centred outcomes in COPD: deconditioning. Eur. Res. Rev. 2006; 15: 42-46.
8. Czaika G., Mehiri S., Grassino A. Respiratory muscle in chronic obsrstuctice lung disease. W: Voelkel N.F., MacNee V. (red.). Chronic obstructive lung diseases. BC Decker Inc. Hamilton, London 2002; 341-351.
9. Wouters E.F.M. A wasting disease. W: Voelkel N.F., MacNee V. (red.). Chronic obstructive lung diseases. BC Decker Inc. Hamilton, London 2002; 364-376.
10. Hogg J.C., Chu F., Utokaparch S. i wsp. The nature of smallairway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 2645-2653.
11. Dahl M., Vestbo J., Lange P., Bojesen S.E., Tybjaerg-Hansen A., Nordestgaard B.G. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007; 175: 250-255.
12. Broekhuizen R., Wouters E.F., Creutzberg E.C., Schols A.M. Elevated CRP mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61: 17-22.
13. Pinto-Plata V.M., Müllerova H., Toso J.F. i wsp. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006; 61: 23-28.
14. Janssen S.P., Gayan-Ramirez G., Vand der Bergh A. i wsp. Interleukin 6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation 2005; 111: 996-1005.
15. Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574-580.
16. Troosters T., Probst V.S., Crul T. i wsp. Resistance training prevents deterioration in quadriceps muscle function during acute exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2010; 181: 1072-1077.
17. Garcia-Aymerich J., Serra I., Gó mez F.P. i wsp. Phenotype and Course of COPD Study Group.: Physical activity and clinical and functional status in COPD. Chest 2009; 136: 62-70.
18. Petersen A.M., Pedersen B.K. The anti-inflammatory effect of exercise. J. Appl. Physiol. 2005; 98: 1154-1162.
19. Stav D., Raz M., Shpirer I. Three years of pulmonary rehabilitation: inhibit the decline in airflow obstruction, improves exercise endurance time, and body-mass index, in chronic obstructive pulmonary disease. BMC Pulm. Med. 2009; 9: 26.
20. Arnardóttir R.H., Sörensen S., Ringqvist I., Larsson K. Two different training programmes for patients with COPD: a randomised study with 1-year follow-up. Respir. Med. 2006; 100: 130-139.
21. Kozielski J., Jastrzebski D. Physical exercise as a component of pulmonary rehabilitation. W: Witkoś J., Błońska-Fajfrowska B., Niebrój L., Gaździk T. (red.). Physiotherapy. Pressing issues of everyday practice. Raleigh: Lulu Enterprises, Inc., 2012; 243-252.
22. Mahler D.A. Pulmonary rehabilitation. Chest 1998; 113: 263S-268S.
23. Hasegawa M., Makita H., Nasuhara Y. i wsp. Relationship between improved airflow limitation and changes in airway calibre induced by inhaled anticholinergic agents in COPD. Thorax 2009; 64: 332-338.
24. Maltais F., Hamilton A., Marciniuk D. i wsp. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005; 128: 1168-1178.
25. O'Donnell D.E., Laveneziana P., Ora J., Webb K.A., Lam Y.M., Ofir D. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. Thorax 2009; 64: 216-223.
26. Berton D.C., Reis M., Siqueira A.C. i wsp. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD. Respir. Med. 2010; 104: 1288-1296.
27. Cazzola M., Segreti A., Stirpe E., Appodia M., Senis L., Matera M.G. Energy expenditure and impact of bronchodilatators in COPD patients. Respir. Med. 2010; 104: 1490-1494.